RPL17 and melanoma: Mice with melanoma rich in macrophages had dramatically enhanced response to immune checkpoint inhibitors and survival when co-treated with IPI-549: Monotherapy with anti-CTLA-4 or anti-PD-1 produced total remission in 20% of cases whilst addition of IPI-549 increased this to 80%.